Below are the three companies in the Biotechnology industry with the highest sales per share. Sales per share is a valuable metric in comparing relative value for companies in the same industry.
Biogen Idec (NASDAQ:BIIB) is highest with sales per share of $23.19. Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products addresses diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis.
Biogen Idec (NASDAQ:BIIB) is currently priced 0.7% above its average consensus analyst price target of $159.90. The stock should discover initial support at its 50-day moving average (MA) of $149.44 and subsequent support at its 200-day MA of $144.14.
Amgen (NASDAQ:AMGN) is next with sales per share of $22.28.
Finishing up the top three is United Therapeutics (NASDAQ:UTHR), with sales per share of $16.38.